Evidence map›Paper›PMID 35678579›Full record

ReviewJournal of the American Medical Informatics Association : JAMIA2022

Standardizing, harmonizing, and protecting data collection to broaden the impact of COVID-19 research: the rapid acceleration of diagnostics-underserved populations (RADx-UP) initiative.

Gabriel A Carrillo, Michael Cohen-Wolkowiez, Emily M D'Agostino, Keith Marsolo, Lisa M Wruck, Laura Johnson, James Topping, Al Richmond, Giselle Corbie, Warren A Kibbe

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of the American Medical Informatics Association : JAMIA, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. COVID-19 Testing Factors Among Great Plains American Indians.Journal of racial and ethnic health disparities · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Gabriel A CarrilloDepartment of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA.
Michael Cohen-WolkowiezDepartment of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA.
Emily M D'AgostinoDepartment of Family Medicine and Community Health, Duke University School of Medicine, Durham, North Carolina, USA.
Keith MarsoloDuke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Lisa M WruckDuke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Laura JohnsonDuke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
James ToppingDuke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Al RichmondCommunity-Campus Partnerships for Health, Raleigh, North Carolina, USA.
Giselle CorbieCenter for Health Equity Research, University of North Carolina, Chapel Hill, North Carolina, USA.
Warren A KibbeDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA.ORCID 0000-0001-5622-7659
Duke University · USCommunity-Campus Partnerships for Health · USUniversity of North Carolina at Chapel Hill · US

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI Laura Fish · 1985 to 2026
$174.8M
RADx-UP SAY YES COVID Test Study (S4)U24MD016258 · NIMHD · DUKE UNIVERSITY · PI COHEN-WOLKOWIEZ, MICHAEL, DAVE, GAURAV J · 2020 to 2023
$116.7M
PREVENTABLE Vanguard PhaseU19AG065188 · NIA · DUKE UNIVERSITY · PI Laura Kristin NEWBY · 2019 to 2026
$96.2M
Support for QA/QC for Prior Approval ProcessUL1TR002553 · NCATS · DUKE UNIVERSITY · PI LI, JENNIFER S, MCNAMARA, JAMES O. · 2018 to 2023
$58.5M
The Duke FUNCTION Center: Pioneering the comprehensive identification of combinatorial noncoding causes of diseaseRM1HG011123 · NHGRI · DUKE UNIVERSITY · PI GREGORY E CRAWFORD, Raluca Gordan · 2020 to 2026
$21.9M
Molecular, Cellular and Tissue Characterization UnitU2CCA233254 · NCI · DUKE UNIVERSITY · PI HWANG, E.SHELLEY, MALEY, CARLO · 2018 to 2023
$11.4M
HEAL Collaboratory Resource Coordinating Center (PRISM) (U24): Bioethics SupplementU24AT010961 · NCCIH · DUKE UNIVERSITY · PI CURTIS, LESLEY H, HERNANDEZ, ADRIAN · 2019 to 2021
$6.4M
Pathways to cardiovascular disease prevention and impact of specialty referral in under-represented racial/ethnic minorities with HIVR01MD013493 · NIMHD · DUKE UNIVERSITY · PI BLOOMFIELD, GERALD SAMUEL · 2018 to 2022
$3.3M
Mentoring in Clinical Pharmacology and Early Phase TrialsK24AI143971 · NIAID · DUKE UNIVERSITY · PI COHEN-WOLKOWIEZ, MICHAEL · 2019 to 2023
$895k
CDC HHS NU38OT000316Centers for Medicare & Medicaid Service 75FCMC18D0047FDA HHS 75F40119C10086FDA HHS U01 FD006292FDA HHS U18 FD006298Medical Device Innovation Consortium 6292-2020-DQ/5U01-FD006292National Institute of Allergy and Infectious Diseases HHSN272201500006INCATS NIH HHS 5UL1-TR002553NCATS NIH HHS UL1 TR002553NCCIH NIH HHS U24 AT010961NCI NIH HHS 1UC2-CA233254NCI NIH HHS P30 CA014236NCI NIH HHS U2C CA233254NHGRI NIH HHS 1RM1-HG011123NHGRI NIH HHS RM1 HG011123NIAID NIH HHS HHSN272201300017CNIAID NIH HHS HHSN272201300017INIAID NIH HHS HHSN272201500006CNIAID NIH HHS K24 AI143971NIA NIH HHS U19 AG065188NICHD NIH HHS HHSN275201000003CNICHD NIH HHS HHSN275201000003INIH HHS 1U24-AT010961NIH HHS 1U24MD016258NIH HHS U24 MD016258NIMHD NIH HHS 1U24-MD016258NIMHD NIH HHS R01 MD013493NIMHD NIH HHS U24 MD016258Patient-Centered Outcomes Research Institute CC2-Duke-2016U.S. Food and Drug Administration 5U18-FD006298
6 · The paper itself

Abstract

objectiveThe Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) program is a consortium of community-engaged research projects with the goal of increasing access to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) tests in underserved populations. To accelerate clinical research, common data elements (CDEs) were selected and refined to standardize data collection and enhance cross-consortium analysis. MATERIALS AND

methodsThe RADx-UP consortium began with more than 700 CDEs from the National Institutes of Health (NIH) CDE Repository, Disaster Research Response (DR2) guidelines, and the PHENotypes and eXposures (PhenX) Toolkit. Following a review of initial CDEs, we made selections and further refinements through an iterative process that included live forums, consultations, and surveys completed by the first 69 RADx-UP projects.

resultsFollowing a multistep CDE development process, we decreased the number of CDEs, modified the question types, and changed the CDE wording. Most research projects were willing to collect and share demographic NIH Tier 1 CDEs, with the top exception reason being a lack of CDE applicability to the project. The NIH RADx-UP Tier 1 CDE with the lowest frequency of collection and sharing was sexual orientation. DISCUSSION: We engaged a wide range of projects and solicited bidirectional input to create CDEs. These RADx-UP CDEs could serve as the foundation for a patient-centered informatics architecture allowing the integration of disease-specific databases to support hypothesis-driven clinical research in underserved populations.

conclusionA community-engaged approach using bidirectional feedback can lead to the better development and implementation of CDEs in underserved populations during public health emergencies.

Indexed as

Biomedical ResearchCOVID-19AccelerationCommon Data ElementsCommunity ParticipationCOVID-19 TestingData CollectionFemaleHumansMaleNational Institute of Neurological Disorders and Stroke (U.S.)SARS-CoV-2Stakeholder ParticipationUnited StatesVulnerable Populationscommon data elementscommunity researchdata privacyhealth equityunderserved populations

Identifiers

PMID35678579
PMCPMC9382379
OpenAlexW4281704151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.